Can text messages break down stigma and boost PrEP access for drug users?

NCT ID NCT07508137

Not yet recruiting Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 4 times

Summary

This pilot study will test a series of brief, private text messages sent via WhatsApp or Telegram to help people who use drugs in Kazakhstan feel more comfortable seeking PrEP, an HIV prevention pill. The messages address stigma, confidentiality worries, and misinformation. Forty participants will complete surveys before and after the 2-3 week program to see if the approach is acceptable and feasible. No medications or lab tests are involved.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: digital micro-intervention (text-based modules via Telegram or WhatsApp)
What this could lead to: If successful, this could point toward a scalable, low-cost way to help people who use drugs overcome stigma and access HIV prevention.
What could go wrong: This is a very small pilot (40 people) with no clinical outcomes—only surveys. It may not translate to real-world PrEP uptake or work in other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG USE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

substance abuse HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG USE HIV

Contacts and locations

Locations

Center for Scientific and Practical Initiatives

Almaty, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.